ETV4 and asthma: In particular, ETV4 and PPARG were the only TFs that met three criteria: (1) highly weighted, (2) significantly differentially active in asthma (FDRVIPER ≤ 0.05), and (3) significantly regulating the asthma biomarker (FDRBIOMARKER ≤ 0.05) (Table 1).